Simone Bier

Simone Bier

Auto-generated profile, based on publicly available information

Simone Bier

Department of Andrology Centre of Reproductive Medicine and Andrology (CeRA) University Hospital of Münster Münster Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2018 in Disease Markers
Verified
Journal Article
Open access
PDF file
SBSimone Bier
Simone Bier
JHJörg Hennenlotter
Jörg Hennenlotter
MEMichael Esser
Michael Esser
SMSarah Mohrhardt
Sarah Mohrhardt
SRSteffen Rausch
Steffen Rausch
TTTilman Todenhöfer
Tilman Todenhöfer
Objectives. To assess the performance of urine markers determined in urine samples from the bladder compared to samples collected from the upper urinary tract (UUT) for diagnosis of UUT urothelial carcinoma (UC). Patients and Methods. The study comprised 758 urine samples either collected from the bladder (n=373) or UUT (n=385). All patients underwent urethrocystoscopy and UUT imaging or ureterorenoscopy. Cytology, fluorescence in situ hybridization (FISH), immunocytology (uCyt+), and nuclear matrix protein 22 (NMP22) were performed. Results. UUT UC was diagnosed in 59 patients (19.1%) (UUT urine) and 27 patients (7.2%) (bladder-derived urine). For UUT-derived samples, sensitivities for cytology, FISH, NMP22, and uCyt+ were 74.6, 79.0, 100.0, and 100.0, while specificities were 66.6, 50.7, 5.9, and 66.7%, respectively. In bladder-derived samples, sensitivities were 59.3, 52.9, 62.5, and 50.0% whereas specificities were 82.9, 85.0, 31.3, and 69.8%. In UUT-derived samples, concomitant bladder cancer led to increased false-positive rates of cytology and FISH. Conclusions. Urine markers determined in urine collected from the UUT exhibit better sensitivity but lower specificity compared to markers determined in bladder-derived urine. Concomitant or recent diagnosis of UC of the bladder can further influence markers determined in UUT urine.

22 December 2014 in Disease Markers
Verified
Journal Article
Open access
PDF file
TTTilman Todenhöfer
Tilman Todenhöfer
JHJörg Hennenlotter
Jörg Hennenlotter
MEMichael Esser
Michael Esser
SMSarah Mohrhardt
Sarah Mohrhardt
SAStefan Aufderklamm
Stefan Aufderklamm
CSChristian Schwentner
Christian Schwentner
Background. The optimal use of urine markers in the surveillance of non-muscle-invasive bladder cancer (NMIBC) remains unclear. Aim of the present study was to investigate the combined and stepwise use of the four most broadly available urine markers to detect tumor recurrence in patients undergoing surveillance of NMIBC.Patients and Methods. 483 patients with history of NMIBC were included. Cytology, UroVysion, fluorescence in situ hybridization (FISH), immunocytology (uCyt+), and NMP22 ELISA were performed before surveillance cystoscopy. Characteristics of single tests and combinations were assessed by contingency analysis.Results. 128 (26.5%) patients had evidence of tumor recurrence. Sensitivities and negative predictive values (NPVs) of the single tests ranged between 66.4–74.3 and 82.3–88.2%. Two-marker combinations showed sensitivities and NPVs of 80.5–89.8 and 89.5–91.2%. A stepwise application of the two-test combinations with highest accuracy (cytology and FISH; cytology and uCyt+; uCyt+ and FISH) showed NPVs for high-risk recurrences (G3/Cis/pT1) of 98.8, 98.8, and 99.1%, respectively.Conclusions. Combinations of cytology, FISH, immunocytology, and NMP22 show remarkable detection rates for recurrent NMIBC. Stepwise two-test combinations of cytology, FISH, and immunocytology have a low probability of missing a high-risk tumor. The high sensitivities may justify the use of these combinations in prospective studies assessing the use of urine markers to individualize intervals between cystoscopies during follow-up.

25 June 2026 in Andrology
Verified
Journal Article
Open access
MAMattia Anfosso
Mattia Anfosso
MSMaria Schubert
Maria Schubert
JCJann‐Frederik Cremers
Jann‐Frederik Cremers
SKSabine Kliesch
Sabine Kliesch
MZMichael Zitzmann
Michael Zitzmann
SBSimone Bier
Simone Bier
Background: Non‐obstructive azoospermia (NOA) represents the most severe form of male infertility. Hypogonadism is common in NOA patients, and normal testosterone (T) levels are considered essential for spermatogenesis. Fertility‐preserving hormonal therapy (FpHT) has been proposed to optimize hormonal milieu and improve sperm retrieval rates (SRR) at microdissection testicular sperm extraction (mTESE), although evidence remains controversial and meta‐analyses have not shown consistent benefit. Aims: To determine whether FpHT improves SRR in hypogonadal men with NOA undergoing mTESE. Methods: We retrospectively evaluated 1256 selected men with NOA (601 Klinefelter syndrome [KS], 655 normal karyotype) from a cohort of 3086 men who underwent mTESE at our tertiary andrology center between 2010 and 2024. Patients with obstructive azoospermia, prior gonadotoxic exposure, or hypogonadotropic hypogonadism were excluded. All participants underwent comprehensive clinical, hormonal, and genetic assessment. Comparisons were performed between eugonadal and hypogonadal patients, and within the hypogonadal group, between those who received FpHT and those who did not. Results: Hypogonadism was present in 49.9% of patients, predominantly in KS ( p < 0.001). FpHT significantly increased serum T levels in both groups (ΔT +3.1 nmol/L in KS; +5.6 nmol/L in 46, XY; p < 0.001). However, despite biochemical normalization, FpHT did not improve SRR in either karyotypic group (overall SRR: 32.4%). Multivariate analysis identified younger age as the sole independent predictor of successful retrieval in KS ( p = 0.011). Conclusion: FpHT restores serum androgen levels but does not improve spermatogenic activity or sperm retrieval rates in men with NOA. These findings support current EAU guidelines and indicate that FpHT should be used to treat symptomatic hypogonadism rather than to enhance fertility outcomes before mTESE.

24 March 2017 in European Urology Supplements
Verified
Journal Article
Closed access
SBS. Bier
S. Bier
JHJörg Hennenlotter
Jörg Hennenlotter
GBG. Beger
G. Beger
LPL. Pavlenco
L. Pavlenco
NFN. Feniuk
N. Feniuk
TTT. Todenhöfer
T. Todenhöfer

7 October 2026 in Andrology
Verified
Journal Article
Open access
PDF file
MAM. Anfosso
M. Anfosso
MSM. Schubert
M. Schubert
JCJf. Cremers
Jf. Cremers
SKS. Kliesch
S. Kliesch
MZM. Zitzmann
M. Zitzmann
SBS. Bier
S. Bier
Click on the article title to read more.